title: Effects of current therapy of Kawasaki disease on eicosanoid metabolism.
abstract: Coronary artery inflammation in Kawasaki disease is accompanied by thrombocytosis and platelet activation. It was hypothesized that abnormal metabolism of bioactive eicosanoids could result from or contribute to these events. Circulating plasma thromboxane B2, 6-keto-prostaglandin F1 alpha and prostaglandin E were measured by double antibody radioimmunoassay in patients with Kawasaki disease before and after aspirin alone or aspirin and intravenous gamma globulin therapy. Plasma prostaglandin E concentrations were normal in all patient groups. Pretreatment thromboxane B2 was elevated compared with age-matched controls, fell moderately with high-dose aspirin (60 to 100 mg/kg/day) and marginally increased with low-dose aspirin (3 to 5 mg/kg/day) 6 to 8 weeks after treatment. Plasma 6-keto-prostaglandin F1 alpha was not detected in 12 of 16 patients before therapy and remained low in all but 1 patients by 6 to 8 weeks. Thromboxane B2 correlated weakly with serum salicylate concentration but had no relation to platelet mass. The results in these patients with Kawasaki disease indicate only partial thromboxane suppression and depressed prostacyclin generation regardless of therapy. This balance favors coronary vasoconstriction and platelet aggregation capable of potentiating myocardial ischemia or infarction. The results justify consideration of higher or more frequent aspirin doses for longer duration and thromboxane receptor blockade in this disease.
authors: Division of Pediatric Critical Care, Boston Floating Hospital, New England Medical Center, Massachusetts 02111.
authors: D R
authors: DR
authors: Fulton
authors: C
authors: C
authors: Meissner
authors: M B
authors: MB
authors: Peterson
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D001241:Aspirin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000188:drug therapy*; D011458:Prostaglandins E / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood*; D013997:Time Factors; D005719:gamma-Globulins / Q000008:administration & dosage
chemical_list: D011458:Prostaglandins E; D005719:gamma-Globulins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D001241:Aspirin